Reviva Pharmaceuticals Faces Delisting Notice

TL;DR

Reviva Pharmaceuticals is on the chopping block for delisting.

AI Summary

Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on October 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Tenzing Acquisition Corp., was incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates potential issues with Reviva Pharmaceuticals' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall viability.

Key Players & Entities

• REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
• Tenzing Acquisition Corp. (company) — Former company name
• October 14, 2025 (date) — Earliest event reported
• October 17, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RVPH Nasdaq Capital Marke
• $35 million — ad failed to maintain a minimum MVLS of $35 million over the previous 30 consecutive busine
• $1.00 m — e Company is not in compliance with the $1.00 minimum bid price requirement set forth i
• $1.00 — ties to maintain a minimum bid price of $1.00 per share and, based upon the closing b

Filing Documents

• rvph20251014_8k.htm (8-K) — 30KB
• 0001437749-25-031278.txt ( ) — 174KB
• rvph-20251014.xsd (EX-101.SCH) — 4KB
• rvph-20251014_def.xml (EX-101.DEF) — 13KB
• rvph-20251014_lab.xml (EX-101.LAB) — 17KB
• rvph-20251014_pre.xml (EX-101.PRE) — 13KB
• rvph20251014_8k_htm.xml (XML) — 5KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 14, 2025, Reviva Pharmaceuticals Holdings, Inc. (the "Company") received a letter (the "MVLS Compliance Letter") from the Listing Qualifications Department (the "Nasdaq Staff") of The Nasdaq Stock Market ("Nasdaq") formally notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement") and that the MVLS Requirement matter is now closed. The MVLS Compliance Letter was pursuant to a previous notice received on August 8, 2025 from Nasdaq Staff indicating, as previously reported, that the Company was not then in compliance with the MVLS Requirement because the Company had failed to maintain a minimum MVLS of $35 million over the previous 30 consecutive business days preceding such previous notice. Since then, Nasdaq Staff has determined that for the last 10 consecutive business days preceding the MVLS Compliance Letter, from September 30, 2025 to October 13, 2025, the Company's MVLS has been $35 million or greater. As previously disclosed, pursuant to the written notice received from Nasdaq on May 13, 2025 (the "Minimum Bid Price Notice"), the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the "Minimum Bid Price Requirement"). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days preceding the Minimum Bid Price Notice, the Company is not currently in compliance with Minimum Bid Price Requirement. As previously reported, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been prov

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Date: October 17, 2025 By: /s/ Narayan Prabhu Narayan Prabhu Chief Financial Officer